Release Date: May 09, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points American Healthcare REIT Inc (NYSE:AHR) reported a strong Q1 2025 with a 15.1% year-over-year same-store NOI growth, driven by their operating portfolio. The company successfully executed a capital allocation initiative, strengthening its financial position and supporting planned external growth. AHR increased its full-year 2025 guidance for same-store NOI growth and NFFO per share, reflecting confidence in continued strong performance. The company has a robust pipeline of over $300 million in acquisitions expected to close by year-end, indicating strong future growth potential. AHR's operating portfolio, particularly the Trilogy and Shop segments, showed impressive growth, with Trilogy achieving a 19.8% increase and Shop a 30.7% increase in same-store NOI. Negative Points The company faced challenges from a difficult flu season, which impacted occupancy rates in some segments. There is a potential risk associated with the regulatory approvals required for some of the acquisitions in the pipeline. The company is still in the early stages of some transactions, which could lead to uncertainties in timing and execution. AHR's focus on selling non-core assets may lead to short-term revenue fluctuations as they transition to higher growth assets. The company is exposed to potential impacts from tariffs and inflation, which could affect construction costs and overall expenses. Q & A Highlights Warning! GuruFocus has detected 6 Warning Signs with AHR. Q: Can you provide more details on your acquisition pipeline and expected closing timelines? A: (Stefan O, Chief Investment Officer) We have a pipeline of over $300 million in acquisitions, with some expected to close in late Q3 and most likely in Q4. These assets are either under LOI, negotiating the LOI, or under contract, giving us a higher certainty of closing. However, regulatory approvals and due diligence could affect timelines. Q: How are you approaching your MOB and triple net portfolios given the higher yields from your operating portfolio? A: (Danny Prosky, President and CEO) We've been reducing our MOB portfolio, focusing on senior housing for better risk-adjusted returns. The triple net segment is also shrinking, but we remain open to opportunities if they arise. Our growth focus is on the operating portfolio, which now constitutes over 70% of our NOI. Q: Can you elaborate on the competitive process and economics of your investment pipeline? A: (Danny Prosky, President and CEO) The pipeline includes a mix of shop and trilogy assets, mostly newer buildings with attractive pricing. Many deals were sourced off-market through existing relationships, allowing us to secure assets without broad competition. The assets are high-quality, with some offering value-add opportunities. Story Continues Q: How are Medicaid and Medicare Advantage rates impacting Trilogy's performance? A: (Gabe Whit, Chief Operating Officer) Medicaid rates are expected to rise with inflation, with potential for additional increases through value-based care components. Medicare Advantage rates are negotiated throughout the year, and we've expanded our contracts, providing a significant tailwind for Trilogy. Q: What strategies are you employing to capture demand during the peak selling season? A: (Danny Prosky, President and CEO) We've implemented rate increases and reduced concessions, which have positively impacted margins. Dynamic pricing is also being used to optimize revenue, allowing us to charge more for premium units and improve overall financial performance. Q: How is Trilogy supporting smaller shop operators to improve operational efficiency? A: (Gabe Whit, Chief Operating Officer) Trilogy offers resources like group purchasing, revenue management, and training to regional operators. This support enhances operational efficiency and care quality, contributing to NOI growth and platform value. Q: Can you discuss the new campus development and future opportunities? A: (Danny Prosky, President and CEO) We typically start 2-3 new campuses annually. The new project in Michigan involves redeveloping an existing building into an integrated senior health campus. We plan to continue expanding with new campuses and developments. Q: What are your expectations for Trilogy's average daily rate growth? A: (Gabe Whit, Chief Operating Officer) The reported dip is due to a shift in bed mix, with more independent living units added. Trilogy achieved a 6% rate increase on the private side, and we expect continued growth as the bed mix stabilizes. For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus. View Comments
American Healthcare REIT Inc (AHR) Q1 2025 Earnings Call Highlights: Strong NOI Growth and ...
You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research.
Start Your Free Trial Now!Not sure where to invest today?
Kalkine’s latest research highlights three companies identified through in-depth analysis and market insights.
Explore these research reports to learn about companies currently being tracked by our analysts and make more informed investment decisions.
View 3 Research ReportsThis information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...